21st week of 2016 patent applcation highlights part 7 |
Patent application number | Title | Published |
20160143813 | INTERACTIVE KIOSK FOR COUNTING, LABELING, AND SHIPPING OF RECALLED MEDICATION CAPSULES - A kiosk according to an embodiment of the present invention includes a housing; a touch screen configured to receive input information from a user; a label printer configured to print output information from the kiosk; a pill drop opening; a pill chute; a drive tube having entry and exit openings, wherein the drive tube has an axis extending through a longitudinal axial centerline thereof, and has an inside surface comprising a helical flute, wherein the entry opening is in communication with the pill chute, and wherein the exit opening is higher than the entry opening such that the axial centerline of the drive tube is inclined; a motor configured to rotate the drive tube to separate and convey pills received through the pill drop opening and the pill chute; and an optical counter configured to count the pills as the pills fall from the exit opening of the drive tube. | 2016-05-26 |
20160143814 | SELF-PACED ERGONOMIC INFANT FEEDING BOTTLE - A self-paced, ergonomic feeding bottle with a substantially-straight back sidewall and an “S”-shaped curved front sidewall; where the curved front sidewall comprises two sections: (1) a convex chest section near the top, and (2) a concave handle section near the bottom, comprising a concave crook and a thin waist. The top-heavy bottle has a single plane of symmetry located between the right and left hand sides of the bottle. An anti-vacuum valve can be inserted into a vent hole. Side positioning markers can be used to achieve zero hydrostatic pressure during use. Anti-roll pads are part of the front sidewall. | 2016-05-26 |
20160143815 | DUAL MATERIAL Y-CONNECTOR - A dual material Y-connector for use in connection with medical tubing systems and the like includes an inner core made of a first material such as a rigid plastic material and an over-layer made of a second material such as a pliable thermoplastic elastomer. The Y-connector comprises a primary arm, a secondary arm and a convergence arm all in fluid communication with one another and may include a tubing segment bonded to the Y-connector convergence arm. The first material can be a transparent copolyester and the second material can be a translucent thermoplastic elastomer. Threaded caps having a multi-indentation configuration can be tethered to one or more arms and be configured to seal one or more Y-connector ports. | 2016-05-26 |
20160143816 | DEVICES AND METHODS FOR PERCUTANEOUS ENDOSCOPIC GASTROSTOMY AND OTHER OSTOMY PROCEDURES - Ostomy tubes, particularly gastrostomy tubes, with improved retention means are provided. More specifically, retention structures, such as bolsters, for gastrostomy tubes are provided, configured to removably assemble to one end of a gastrostomy tube to facilitate replacement and removal of the tube. The retention structures provided herein may comprise one or more removably assembled retention elements. Further provided are gastrostomy tubes comprising such retention structures, and methods for percutaneous endoscopic gastrostomy utilizing same. | 2016-05-26 |
20160143817 | CLOSED LOOP SYSTEMS AND METHODS FOR OPTIMAL ENTERAL FEEDING AND A PERSONALIZED NUTRITION PLAN - There is provided a computer-implemented method for calculating a gastric emptying rate from a stomach lumen into a small intestine of a patient, comprising: using at least one processor for executing the following during an enteral tube feeding of a stomach of the patient by a feeding mechanism: analyzing outputs of at least one stomach sensor located within the stomach for detecting a stop feeding condition; pausing the enteral tube feeding in response to a detection of the stop feeding condition; after a predefined period of time, restarting the enteral tube feeding until the stop condition is redetected by an analysis of said outputs; calculating a gastric emptying rate based on an amount of feeding content delivered during a period between the restarting and the redetection; and instructing the feeding mechanism to adapt a feeding rate of the enteral tube feeding according to the gastric emptying rate. | 2016-05-26 |
20160143818 | DENTAL COMPOSITION - A dental cement hardened by a cement reaction involving the specific polymerizable polyacidic polymer and optionally additional crosslinkable groups, has reduced shrinkage and improved mechanical properties, in particular with regard to flexural strength and fracture toughness. Moreover, the specific polymerizable polyacidic polymer of the present invention contains a high number of acidic groups which is not reduced by the presence of polymerizable moieties, whereby water solubility of the uncured polymer is not impaired by the presence of the polymerizable moieties. | 2016-05-26 |
20160143819 | FULLY USEABLE SOAP - An economical soap bar which includes a soap bar body with a hollow interior and an insert occupying the hollow interior, preferably with projecting fingers that penetrate into the soap bar body. The projecting fingers or follicles are designed to penetrate into the body of the soap and provide a massaging sensation to the body by being formed of flexible, hair-like or follicles that are very flexible, or by providing the follicles as combination of flexible fingers, some of which have a rigidity greater than other projecting fingers that are more flexible. | 2016-05-26 |
20160143820 | COLORFUL GEL AND PREPARATION METHOD THEREOF - The present invention provides a colorful gel, comprising following components by weight percentage: 20.0% to 25.0% by weight of glycerin, 20.0% to 25.0% by weight of propylene glycol, 1.0% by weight of sea algae extract, 0.05% by weight of disodium EDTA, 0.06% by weight of allantoin, 0.05% by weight of sodium hyaluronate, 20.0% to 30.0% by weight of cyclopentasiloxane, 5.0 to 10.0% by weight of dimethicone, 0.5 to 1.0% by weight of sodium acrylate/sodium acryloyldimethyl taurate copolymer, 0.25 to 0.5% by weight of isohexadecane, 0.2% to 0.4% by weight of polysorbate-80, 1.5% by weight of soluble collagen, 0.5% by weight of caprylyl glycol, and water as the rest. The present invention also provides a preparation method of the colorful gel. The colorful gel of the present invention has excellent moisturizing performance, and it can keep moisturizing skin, which is safe and healthy. | 2016-05-26 |
20160143821 | PACKAGED PRODUCT INCLUDING A CONTAINER WITH A CONSUMER MEDIUM AND A PROPELLANT MEDIUM STORED THEREIN - A packaged product is provided that includes a container with a consumer medium and a propellant medium stored therein. The container is a non-barrier type aerosol container. The propellant medium includes a hydrocarbon agent. In some embodiments, the consumer medium is water-based and at least substantially free of solvents. In some embodiments, the propellant medium additionally includes an organoflourine agent and/or carbon dioxide. | 2016-05-26 |
20160143822 | EYELASH ORNAMENT COSMETIC - Provided is an eyelash ornament cosmetic comprising at least a polymer emulsion and an extender wherein an average particle diameter of the extender is 1 μm or less, wherein droplets applied on the tips of eyelashes are dried and turned into fine spherical resin balls, and the tips of the eyelashes are ornamented to make it possible to provide the eyes with brilliantness and loveliness. | 2016-05-26 |
20160143823 | Bath Salt Composition - The present invention is directed to a granulated composition comprising a salt encapsulated by a composition that comprises at least one wax. | 2016-05-26 |
20160143824 | LONG-WEAR COSMETIC COMPOSITION - The present invention relates to a cosmetic composition comprising: (i) at least one oxide of an alkaline earth metal (ii) at least one metal soap, preferably a metal salt of C | 2016-05-26 |
20160143825 | COMPOSITIONS - Suggested is a composition comprising
| 2016-05-26 |
20160143826 | PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION - The present invention relates to a process for dyeing human keratin fibres, in which use is made of one or more metal catalysts and a composition (A) comprising: (a) at least 10% by weight of one or more fatty substances, (b) one or more oxidation bases of formula (I) or (II), the addition salts thereof, solvates thereof and mixtures thereof: Formula (I), Formula (II) (c) one or more chemical oxidizing agents other than atmospheric oxygen. The invention also relates to a multi-compartment device and to a composition comprising all of the above-mentioned ingredients. | 2016-05-26 |
20160143827 | HAIR CONDITIONER - The present invention relates to a composition comprising one or more quaternary ester ammonium compounds (a), one or more amidoamine compounds (b), wherein the weight ratio between the one or more quaternary ester ammonium compounds (a) and the one or more amidoamine compounds (b) is within a range of 1:5 to 5:1, and one or more fatty alcohols (c). The present invention also relates to a composition that is solid at room temperature, to a hair conditioner composition and to a method to prepare the hair conditioner composition by dispersing the solid composition in water at moderate temperatures. | 2016-05-26 |
20160143828 | Use Of Special N-Alkyl-N-Acylglucamines For Conditioning Hair In Hair Washing Agents - The invention relates to N-alkyl-N-acylglucamines of formula (I), which exhibit in hair-washing agents comprising an aqueous surfactant system with at least one anionic surfactant, a hair-conditioning effect, wherein, in formula (I), Ra is a linear or branched, saturated or unsaturated C | 2016-05-26 |
20160143829 | PHOTOLABILE PRO-FRAGRANCES - Fragrances that provide a scent of freshness tend to be volatile and are therefore not very economical when used in typical applications such as washing or cleaning processes, so they have to be used in relatively large quantities to be able to produce adequate effects. The disclosed photolabile pro-fragrances provide a much longer-lasting sense of fragrance, in particular with a scent of freshness, when used in typical applications, thus allowing said fragrances to be used economically. | 2016-05-26 |
20160143830 | SKIN COMPOSITIONS AND METHODS - The invention provides skin compositions containing a mixture of milled particles having different sizes less than 50 microns in diameter of vitamins in a biocompatible carrier. | 2016-05-26 |
20160143831 | UV SCREENING COMPOSITION COMPRISING A UV FILTER, AN ORGANOPOLYSILOXANE FUNCTIONALIZED WITH A UV ABSORBER AND POROUS SILICA AND/OR POLYMETHYLMETHACRYLATE PARTICLES - The present invention relates to a topical composition comprising a hydrophilic benzimidazole type UVB filter, an organopolysiloxane functionalized with at least one UV-light absorbing group, and highly porous silica and/or highly porous crosslinked polymethylmethacrylate beads having a particle size D | 2016-05-26 |
20160143832 | COSMETIC USE AS DEODORANT ACTIVE AGENT OF A SILICEOUS MATERIAL OBTAINED BY HYDROLYSIS AND CONDENSATION OF A TETRAALKOXYSILANE AND OF A C7-C20-ALKYLTRIALKOXYSILANE - The invention thus relates to the cosmetic use of a siliceous material that may be obtained by hydrolysis and condensation, in the presence of water, of at least one tetraalkoxysilane of formula (I) below: Si(OR2)4 (I) and of an alkyltrialkoxysilane of formula (II) below: R | 2016-05-26 |
20160143833 | BUBBLE TYPE WATERLESS SHAMPOO COMPOSITION - A bubble type waterless shampoo composition. 0.1 to 5 wt % of potassium cocoyl hydrolyzed collagen and 0.01 to 2 wt % of palmitoyl oligopeptide as natural surfactants. 0.1 to 7 wt % of cocamidopropyl betaine as an amphoteric ion. 0.01 to 0.8 wt % of a citric acid as an organic acid. 0.1 to 4 wt % of sodium carbonate as inorganic salt. 0.01 to 0.5 wt % of | 2016-05-26 |
20160143834 | HAIR CARE COMPOSITIONS COMPRISING DEHYDROXANTHAN GUM - Provided is a hair care composition for providing improved root lift including at least 0.1% dehydroxanthan gum, from about 0.2% to about 1% of a panthenol compound, from about 0.1% to about 10% of a rheology modifier, and a carrier. | 2016-05-26 |
20160143835 | METHOD OF ACHIEVING IMPROVED HAIR FEEL - A method of achieving improved hair feel. The method comprises applying to hair a composition comprising: (a) a specific cationic guar polymer; (b) a specific cationic copolymer; (c) an anti-dandruff active; (d) a cosmetically acceptable carrier; (e) a surfactant; wherein the weight ratio of (a):(b) is from about 1000:1 to about 3.5:1; and wherein the sum of (a)+(b) is an amount of from about 0.0001% to about 0.7%, by total weight of the composition. The composition forms coacervate particles upon dilution of the composition with water and the coacervate particles have a squeeze flow viscosity of from about 1 cP to about 100 cP. The percentage of coacervate particles with a floc size of greater than about 20 micron is from about 1% to about 60% and the on-scalp deposition of the anti-dandruff active is at least about 1 microgram/cm | 2016-05-26 |
20160143836 | SKIN ENGAGING MEMBER COMPRISING ETHYLENE VINYL ACETATE - A skin engaging member suitable for use in a hair removal device, said skin engaging member comprising ethyl vinyl acetate having a low level of vinyl acetate and a water soluble polymer. | 2016-05-26 |
20160143837 | VARIABLE COLOR TRANSPARENT LIP BALM AND PREPARATION METHOD THEREOF - The present invention provides a variable color transparent lip balm, consisting of following components by weight percent: 4.0 to 5.0% by weight of dibutyl lauroyl glutamide, 2.0 to 3.0% by weight of polyamide-3, 15.0 to 20.0% by weight of bis-stearyl ethylenediamine/neopentyl glycol/stearyl hydrogenated dimer dilinoleate copolymer, 46.65 to 49.60% by weight of C12-15 alkyl benzoate, 1.0 to 3.0% by weight of heptyl undecylenate, 9.0 to 11.0% by weight of C10-30 cholesterol/lanosterol esters, 10.0 to 15.0% by weight of hydrogenated C6-20 polyolefin, 1.5 to 2.5% by weight of dextrin isostearate, 0.05 to 0.1% by weight of eosin yellowish and 0 to 0.8% by weight of excipient. The transparent lip balm of the present invention has good transparency, and excellent variable color effect. | 2016-05-26 |
20160143838 | POLYMERIC COMPOSITIONS CONTAINING IR-EMITTING/ABSORBING ADDITIVES AND SHAPED ARTICLES COMPRISED THEREOF - Polymeric compositions containing additives having properties of emission and/or absorption of radiation in the long infrared region, and articles shaped therefrom are produced, including yarns and textile articles such as fabrics or knits; such additives include organic additives or inorganic fillers which have a capacity for absorption/emission of radiation in the infrared region, in a wavelength range of from 2 μm to 20 μm, and also a polymeric substrate, with the proviso that the inorganic fillers may be selected from among oxides, sulfates, carbonates, phosphates and silicates, and such inorganic fillers having an average particle size of less than 2 μm. | 2016-05-26 |
20160143839 | WATER-FREE OIL/THICKENING MIXTURES AS A BASIS FOR COSMETIC SOFT SOLID AND/OR STICK PREPARATIONS - The invention relates to water-free compositions, having: at least one oil, and a combination of thickeners, including: a) at least one silicone elastomer, b) at least one straight-chained or branched, saturated or unsaturated alcohol having more than 18 carbon atoms, and c) at least one clay mineral mixture modified with quaternary ammonium compounds. The water-free compositions are suitable in particular as soft solid preparations for use on the human skin. In particular, the compositions are suitable as a soft solid antiperspirant composition. | 2016-05-26 |
20160143840 | SKIN COMPOSITIONS AND METHODS OF USE THEREOF - Provided are body corrective cosmetic formulations and methods of use thereof. | 2016-05-26 |
20160143841 | COMPOSITION COMPRISING A COMBINATION OF AN ACRYLIC POLYMER, A SILICONE COPOLYMER AND AN AMINO ACID OR AMINO ACID DERIVATIVE - The present invention relates to a composition for treating keratin fibres, comprising at least an aqueous dispersion of hybrid hydrophobic film-forming acrylic polymer particles, at least one linear block silicone copolymer and at least one amino acid or amino acid derivative. | 2016-05-26 |
20160143842 | ANHYDROUS COMPOSITION WITH LIGHT TEXTURE FOR APPLICATION TO THE SKIN - Cosmetic compositions include, based in each case on the total weight of the composition, 0 to 3% by weight, in particular 0 to 2% by weight, of free water, one or more liquid oils in a total amount of from 40 to 80% by weight, in particular from 50 to 75% by weight, in particular from 60 to 70% by weight, at least one wax, solid dispersed in particulate form. The cosmetic composition has a viscosity of from 300 000 to 800 000 mPas, in particular from 400 000 to 600 000 mPas, has a density of from 0.95 to 1.10 g/cm3 at 20° C., has a light texture and can be spread easily on a substrate. If the substrate is skin, a pleasant skin feel is conveyed. | 2016-05-26 |
20160143843 | SKIN CREAM - The present disclosure encompasses formulations, and methods of manufacture and use thereof, for topical application to and conditioning of human skin. The formulations disclosed comprise an effective amount of at least one steroidal agent, plant extract, viscosity-adjusting agent, anti-oxidant. In particular, the formulations comprise an effective amount micronized progesterone and are used for topical application to the skin of men. | 2016-05-26 |
20160143844 | Drug Delivery Systems and Use Thereof - The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration. | 2016-05-26 |
20160143845 | QUICK DISSOLVE NUTRITIONAL POWDER - The present disclosure provides a rapidly disintegrating orally administrable powder. The powder may include an active ingredient such as a dietary supplement. Methods of using the same are also provided herein. | 2016-05-26 |
20160143846 | Methylphenidate Extended Release Chewable Tablet - An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile. | 2016-05-26 |
20160143847 | FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS - The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 2016-05-26 |
20160143848 | NEAT LIQUID PHARMACEUTICAL FORMULATIONS - Essentially non-aqueous liquid pharmaceutical formulations are formed by mixing at least one pharmaceutically active ingredient and at least one other compound capable of interacting with the active pharmaceutical ingredient through non-covalent interactions to form a low-temperature transition mixture. The stable liquid formulations are readily obtained, even with drugs that are poorly soluble and/or unstable in water. | 2016-05-26 |
20160143849 | METHODS OF TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS - Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period. | 2016-05-26 |
20160143850 | Oral Pharmaceutical Compositions Comprising Imatinib Mesylate - The invention relates to a granulate composition comprising 90-99.95% w/w of Imatinib mesylate, 0.05-0.2% w/w of binder and 0-8% w/w of disintegrant, wherein the granulate composition is prepared using binder in isopropyl alcohol solvent. | 2016-05-26 |
20160143851 | PREPARATION OF POLYLACTIDE-POLYGLYCOLIDE MICROPARTICLES HAVING A SIGMOIDAL RELEASE PROFILE - The present invention relates to preparation of biodegradable microparticles formed from polylactide-polyglycolide copolymers (PLGA) polymer and how to achieve sigmoidal release of active pharmaceutical compound from the microparticles. In particular, the present invention relates to emulsification of an inner/oil phase to an outer/water phase followed by quenching and a single drying step for the preparation of microparticles having a preferred release profile of preferably basic/nucleophilic compounds such as risperidone. Alternatively the present invention is also suitable for hydrophobic compounds that have poor water-solubility and a high drug loading of >20% w/w is required. The release profile can be controlled by adjusting the degree of saturation of the outer/water phase with the organic solvent used in the inner/oil phase, the polymer concentration of the inner/oil phase and the temperature at the quenching step. In particular, an initial lag phase and a substantially sigmoidal release profile are achieved by using an outer aqueous phase over saturated with the solvent used in the inner phase at emulsification step, in combination with a low temperature during quenching. | 2016-05-26 |
20160143852 | LYOPHILIZED THERAPEUTIC PEPTIBODY FORMULATIONS - The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody. | 2016-05-26 |
20160143853 | METHOD OF PREPARING LYOPHILIZED POWDER FOR INJECTION COMPRSING ALOE AND PANAX PSEUDO-GINSENG - A method of preparing a lyophilized powder for injection, including: (1) weighing and mixing aloe powder and | 2016-05-26 |
20160143854 | METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET - An oral dexmethylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated dexmethylphenidate-ion exchange resin complex, a barrier coated dexmethylphenidate-ion exchange resin complex-matrix, and an uncomplexed dexmethylphenidate active component. Following administration of a single dose of the extended release dexmethylphenidate chewable tablet, a therapeutically effective amount of dexmethylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile. | 2016-05-26 |
20160143855 | STABLE PHARMACEUTICAL COMPOSITIONS OF THYROID HORMONE DRUG - The present invention relates to pharmaceutical compositions comprising a thyroid hormone drug. The invention also relates to processes for the preparation of such compositions. | 2016-05-26 |
20160143856 | CAPSULE DOSAGE FORM OF METOPROLOL SUCCINATE - The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation. | 2016-05-26 |
20160143857 | HYBRID ALGINATE-SILICA BEADS AND METHOD FOR OBTAINING THEM - A hybrid silica bead having a millimeter scaled-size is adapted for the entrapment of a component or a bioactive substance. The bead is formed of a porous core including a hybrid alginate-silica and an external porous layer having silica and a silica concentrator. A one-pot process prepares hybrid beads for use of the beads for the entrapment of a component or a bioactive substance. | 2016-05-26 |
20160143858 | Tamper Resistant Oral Dosage Forms - Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent. | 2016-05-26 |
20160143859 | SYSTEM GENERATING A CONSTRAINT FIELD, AND MEDICAL DEVICE IMPLEMENTING THE SAME - Disclosed is a system including (1) an injection device including injectable magnetizable nanoparticles and a component for injecting the same, and (2) a unit for applying a constraint physically and/or mechanically to a tumor associated to an neoangiogenic network where, after having been injected, the particles are retained. Also disclosed is a method for treating tumors, especially tumors associated with a neoangiogenic network, including the steps of: injecting a composition including magnetizable nanoparticles; optionally performing imaging using an imaging device to detect a concentration of nanoparticles retained in the neoangiogenic network; and applying a contact-free constraint onto a tumor in vivo, by a gradient of magnetic field and the application being directed to the tumor region. | 2016-05-26 |
20160143860 | Thin Film With Non-Self-Aggregating Uniform Heterogeneity And Drug Delivery Systems Made Therefrom - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. | 2016-05-26 |
20160143861 | COMPOSITIONS COMPRISING HYDROXYTYROSOL, RESVERATROL, LYCOPENE, FLAVANOLS, AND/OR FLAVONOIDS AND USE THEREOF - The present invention refers to novel compositions comprising hydroxytyrosol, resveratrol, lycopene, flavanols, and/or flavonoids and their use in treating and/or preventing pro-inflammatory diseases or disorders and ROS-mediated diseases or disorders. This invention also generally relates to compositions and to methods of using the compositions to increase tissue oxygenation. | 2016-05-26 |
20160143862 | METHOD OF USING BETA-IONONE TO TREAT AND PREVENT DISEASE INDUCED BY PROPIONIBACTERIUM ACNES - A method of using beta-ionone, E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-one, treats and prevents diseases otherwise induced by | 2016-05-26 |
20160143863 | DISINTEGRANT FREE COMPOSITION OF CINACALCET - The present invention relates to pharmaceutical composition of Cinacalcet or a pharmaceutically acceptable salt thereof comprising diluents, binders and lubricants, wherein said composition is substantially free of disintegrant. It further relates to process for preparing such compositions. | 2016-05-26 |
20160143864 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS OF METOPROLOL - The present invention relates to timed extended-release pharmaceutical compositions comprising metoprolol and an extended-release polymer. The pharmaceutical compositions of the present invention exhibit an in-vivo lag time of at least 2 hours as and a T | 2016-05-26 |
20160143865 | METHODS OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) USING CYSTEAMINE PRODUCTS - The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). | 2016-05-26 |
20160143866 | Combination Therapy for Administration of Monoclonal Antibodies - A combination therapy is disclosed for the treatment of a patient, such as a human, with a monoclonal antibody. The methods can include administering to a patient a monoclonal antibody, for example, a TNT-alpha inhibitor such as adalimumab, certolizumab pegol, golimumab, and infliximab; and administering to the patient colchicine. The present teachings also provide a therapeutic combination and a kit including the therapeutic combination. | 2016-05-26 |
20160143867 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER - The invention relates to methods and pharmaceutical compositions for treating cancer. In particular, the present invention relates to a compound selected from the group consisting of gamma-hydroxybutyrate (GHB), GHB derivatives, and GHB structurally-related compounds thereof, or a pharmaceutically acceptable salt thereof for use in the treatment of cancer in a subject in need thereof. | 2016-05-26 |
20160143868 | TREPROSTINIL ADMINISTRATION BY INHALATION - Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil. | 2016-05-26 |
20160143869 | STABLE BROMFENAC SOLUTION - The present invention provides a stable, aqueous solution comprising bromfenac or a pharmacologically acceptable salt, polymorph, ester or hydrate thereof and/or pharmaceutically acceptable excipients wherein the invention is preferably devoid of an alkyl aryl polyether alcohol type polymer such as tyloxapol, a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate and BAC. Also the present invention is preferably devoid of antioxidants such as sulfite but not limited to sodium sulfite, potassium sulfite and the like. The present invention also provides for a method for treating ocular inflammation and pain, e.g., after cataract surgery, wherein the method comprises topical application of a formulation according to the present invention to the eye of a patient in need thereof. | 2016-05-26 |
20160143870 | IDO INHIBITORS - There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. | 2016-05-26 |
20160143871 | AGENT FOR ALLEVIATING SIDE EFFECTS IN CANCER CHEMOTHERAPY - Agents containing (A) cystine or a derivative thereof and (B) theanine, in combination, are useful for reducing side effects of cancer chemotherapy, can reduce various side effects of cancer chemotherapy, and can improve the treatment completion rate of cancer chemotherapy. | 2016-05-26 |
20160143872 | TRIACYLGLYCEROL-BASED LIPID COMPOSITION - The invention relates to a lipid composition comprising fatty acids mainly in the form of triacylglycerols, in which composition at least 50% of the fatty acids are 14-methyl pentadecanoic acids, and at least 8% of the fatty acids are 12-methyl tetradecanoic acids, the percentages being expressed by weight with respect to the total fatty acids of the composition. | 2016-05-26 |
20160143873 | GEL COMPOSITIONS - Substantially anhydrous topical gel compositions comprising ingenol-3-angelate as a suspension in non-aqueous carriers. | 2016-05-26 |
20160143874 | HISTONE DEACETYLASE INHIBITORS - In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for exmaple. The present invention also provides methods for preparing compounds of the invention and intermediates thereto. | 2016-05-26 |
20160143875 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OBESITY IN A SUBJECT IN NEED THEREOF - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity. | 2016-05-26 |
20160143876 | MAINTENANCE THERAPY REGIME/REGIMEN FOR THE TREATMENT OF ACNE - A maintenance therapy regimen is described for the treatment of acne related diseases. The novel therapy regimen follows a course of oral antibiotic therapy with a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide. | 2016-05-26 |
20160143877 | COMPOSITION FOR SUPPRESSING ADIPOCYTE DIFFERENTIATION, FOR REDUCING FAT ACCUMULATION AND/OR FOR PROMOTING ADIPONECTIN SECRETION AND USAGE FOR SAID COMPOSITION - The present invention relates to a composition for suppressing adipocyte differentiation, for reducing fat accumulation in adipocytes and/or for promoting adiponectin secretion from adipocytes, including sesaminol as an active component. The present invention also relates to a method for suppressing adipocyte differentiation, for reducing fat accumulation in adipocytes and/or for promoting adiponectin secretion of adipocytes, including administering a composition including sesaminol as an active component. | 2016-05-26 |
20160143878 | ANTIBACTERIAL AGENT - An antibacterial agent comprising a compound represented by the following general formula (I), which can exhibit potent antibacterial activity against bacteria that have acquired resistance to quinolones (in the formula, R | 2016-05-26 |
20160143879 | METHODS OF TREATING ULCERS AND RELATED SYMPTOMS IN NON-HUMAN ANIMALS - Provided are methods and compositions for treating and preventing ulcers, ulceratic conditions and/or the symptoms thereof, including gastric, intestinal, e.g., duodenal, and colonic ulcers in non-human animals, especially horses. The methods involve treating an afflicted animal a compositions comprising effective amounts of one or more acid reducing or inhibiting drugs, such as antacids and/or a proton-ion pump inhibitors, and a therapeutically effective amount of a proanthocyanidin polymer from | 2016-05-26 |
20160143880 | Use of Glycopyrrolate for Treating Tachycardia - The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease. | 2016-05-26 |
20160143881 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I - The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy. | 2016-05-26 |
20160143882 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS - The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent. | 2016-05-26 |
20160143883 | METHOD OF TREATING THROMBOCYTOPENIA - Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human. | 2016-05-26 |
20160143884 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) - Provided are methods of treating or inhibiting Human Immunodeficiency Virus (HIV) infection, or treating or inhibiting Acquired Human Immunodeficiency Syndrome (AIDS) in a subject in need thereof, comprising administering an Hsp90 inhibitor in a therapeutically effective amount. | 2016-05-26 |
20160143885 | Treatment Method for Steroid Responsive Dermatoses - Invented is a method of treating steroid responsive dermatoses in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a compound selected from the group consisting of: N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof, and the compound N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof, to such mammal. | 2016-05-26 |
20160143886 | Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury - A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition can include a compound which is a combination of dantrolene and a residue of FMOC-valine. This composition can be used to provide a faster and higher CNS penetration than heretofore experienced with dantrolene. In another form, dantrolene may be formulated as a pro-drug, a pro-pro-drug and the like. | 2016-05-26 |
20160143887 | FORMULATIONS OF BENDAMUSTINE - Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C. | 2016-05-26 |
20160143888 | FORMULATIONS OF BENDAMUSTINE - Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C. | 2016-05-26 |
20160143889 | TREATMENT OF GOUT AND HYPERURICEMIA - Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described. | 2016-05-26 |
20160143890 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA - There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT | 2016-05-26 |
20160143891 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA - Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS. | 2016-05-26 |
20160143892 | Composition for the Management of Nausea and Vomiting - A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO | 2016-05-26 |
20160143893 | SULFOXIMINE SUBSTITUTED 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES AND THEIR USE AS CDK9 KINASE INHIBITORS - The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). | 2016-05-26 |
20160143894 | PROCESS FOR THE PREPARATION OF APIXABAN - A crystalline Form N-1 of apixaban substantially free from one or more of: 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid; 7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; or methyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate, relative to apixaban by area percentage of HPLC and having a mean particle size equal to or greater than 100 μm. | 2016-05-26 |
20160143895 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C - The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I) | 2016-05-26 |
20160143896 | CHIRAL 1-(4-METHYLPHENYLMETHYL)-5-OXO--PYRROLIDINE-2-CARBOXAMIDES AS INHIBITORS OF COLLAGEN INDUCED PLATELET ACTIVATION AND ADHESION - Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion. The present invention provides chiral (2S)-1-(4-methyl-phenylmethyl)-5-oxo-(3S)-{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)-{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p-methylphenylmethyl)1pyroglutamate in good chiral purity. | 2016-05-26 |
20160143897 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND - The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder. | 2016-05-26 |
20160143898 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2016-05-26 |
20160143899 | METHOD FOR TREATING ABNORMAL B-AMYLOID MEDIATED DISEASES - A method for treating abnormal β-amyloid mediated diseases is disclosed, comprising administering a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises an indolylquinoline derivative represented by the following formula 1: | 2016-05-26 |
20160143900 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION - The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection. | 2016-05-26 |
20160143901 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA - This disclosure provides pharmaceutical compositions comprising dextromethorphan in combination with quinidine, and methods for treating agitation and/or aggression in subjects with dementia by administering such compositions. | 2016-05-26 |
20160143902 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY - Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like. | 2016-05-26 |
20160143903 | METHODS OF PROVIDING WEIGHT LOSS THERAPY IN PATIENTS WITH MAJOR DEPRESSION - Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression. | 2016-05-26 |
20160143904 | OLIGOMER MODIFIED DIAROMATIC SUBSTITUTED COMPOUNDS - The invention relates to (among other things) oligomer modified diaromatic substituted compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds. | 2016-05-26 |
20160143905 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS - Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof. | 2016-05-26 |
20160143906 | EFFICACIOUS TREATMENT OF NSCLC AND PREDICTIVE CLINICAL MARKER OF THE RESPONSIVENESS OF A TUMOUR TO A TREATMENT - The present invention relates to a beneficial treatment of tumours in patients suffering from NSCLC, and to a clinical marker useful as predictive variable of the responsiveness of tumours in patients suffering from NSCLC. The present invention further relates to a method for selecting patients likely to respond to a given therapy, wherein said method optionally comprises the use of a specific clinical marker. The present invention further relates to a method for delaying disease progression and/or prolonging patient survival of NSCLC patients, wherein said method comprises the use of a specific clinical marker. | 2016-05-26 |
20160143907 | Methods and Compositions for Treating Clostridium difficile Associated Disease - Methods for treating a subject infected with | 2016-05-26 |
20160143908 | COMPOSITION FOR REDUCING NERVOUS SYSTEM INJURY AND METHOD OF MAKING AND USE THEREOF - This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof. | 2016-05-26 |
20160143909 | PHARMACEUTICAL COMPOSITION - Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity. | 2016-05-26 |
20160143910 | METHODS OF TREATING CANCER AND PREVENTING CANCER DRUG RESISTANCE - Provided herein are methods of treating and/or preventing cancer drug resistance using antagonists of KDM5. | 2016-05-26 |
20160143911 | STABLE AND WATER SOLUBLE PHARMACEUTICAL COMPOSITIONS COMPRISING PEMETREXED - The present invention relates to a solid pharmaceutical composition comprising pemetrexed and a solubilizing amount of meglumine or tromethamine. The composition is sufficiently stable for purpose of making pharmaceutical formulations, particularly lyophilized formulations, and is sufficiently soluble in water for purposes of using in parenteral administration. | 2016-05-26 |
20160143912 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION - Disclosed are methods for treating cancer and precancerous conditions with PDE10A specific inhibitors and diagnosis of neoplastic diseases based on elevated levels of PDE10A. | 2016-05-26 |